More of us
ian Wilmut, the scientist who created Dolly, the world's first mammal cloned from an adult cell has struck a million-dollar deal with a us company to work on human cloning. According to a report in the London Daily Telegraph , Wilmut had agreed to help develop techniques to clone a patient's own cells for transplant, which could provide treatment for a wide range of degenerative diseases.
The project is a collaboration between the Roslin Institute, near Edinburgh, where Dolly was cloned in 1997, and the Californian-based company Geron. Wilmut will receive 83,000 shares of Geron, each worth us $12.
The report said that the new research will have many applications including insulin-producing cells to treat diabetes, nerve cells for stroke, Parkinson's disease and Alzheimer's patients, muscle cells to treat heart attacks and liver cells for the treatment of hepatitis. Producing tissue and cells for transplant will require the cloning of early human embryos, Wilmut said.
Related Content
- First food: business of taste
- Navigating the Indian energy trilemma: the role of liquefied petroleum gas
- A global incentive scheme to reduce carbon emissions
- Judgment of the National Green Tribunal regarding pollution of river Yamuna at Agra and Mathura-Vrindavan due to discharge of untreated sewage in the river, 24/04/2024
- Global report on food crises 2024
- Scaling up anticipatory actions for food security: anticipatory action year in focus 2023